(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

G00002

(43) International Publication Date
4 July 2002 (04.07.2002)

PCT

(10) International Publication Number
WO 02/051483 A1

(51) International Patent Classification[7]: A61M 15/00, A61K 9/00, B65D 83/14

(21) International Application Number: PCT/GB01/05749

(22) International Filing Date:
21 December 2001 (21 12 2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0031502.8	22 December 2000 (22.12.2000)	GB
0128612.9	29 November 2001 (29 11.2001)	GB

(71) Applicant *(for all designated States except US)*: **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB)

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **GODFREY, Anne, Pauline** [GB/GB]. GlaxoSmithKline, Park Road, Ware, Hertfordshire SG12 0DP (GB) **WARBY, Richard** [GB/GB]. Bespak plc, Bergen Way, Kings Lynn, Norfolk PE30 2JJ (GB).

(74) Agent: **DALTON, Marcus, Jonathan, William**; GlaxoSmithKline, Corporate Intellectual Property, 980 Great West Road, Brentford, Middlesex TW8 9GS (GB)

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette

162162

WO 02/051483 A1

(54) Title: METERED DOSE INHALER FOR SALMETEROL XINAFOATE

(57) Abstract: A container, and use thereof, comprising a canister sealed with a metering valve, having a metering chamber, which contains a pharmaceutical aerosol formulation consisting essentially of(A) particulate salmeterol xinafoate optionally in combination with another drug useful in inhalation therapy, suspended in (B) a liquefied propellant gas comprising 1,1,1,2,3,3,3-heptafluoro-n-propane, 1,1,1,2-tetrafluoroethane or a mixture thereof;wherein the formulation is substantially free of surfactant and components having polarity higher than the liquefied propellant gas, said valve characterised in that it contains one or more sealing gaskets substantially constructed from of a polymer of EPDM and the metering chamber surface presents a substantially fluorinated surface to the formulation.